ArticleThe Lancet regional health. Western Pacific2026
HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study.
Ying Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.